Search

Secondary leukemogenesis in the context of T-cell based immunotherapies project

An SWG Grant-supported project initiated by the EHA SWG on Immune Therapies for Hematologic Disorders.

Read more

Ibrutinib improves survival in CLL and SLL patients: Results From the RESONATE Study.

 

Patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL) who experience short response duration or adverse cytogenetics have poor outcomes.

Read more

Sustainability

Actions we're taking to reduce the environmental impact of our flagship event: the EHA Congress.

Read more

Treatment and survival of patients with chronic myeloid leukemia (CML) in Europe

Since the introduction of tyrosine kinase inhibitors into the treatment of CML survival times have greatly improved.

Read more

Pomalidomide prolongs survival in refractory myeloma patients

MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…

Read more

Infections in Hematology

The SWG on Infection in Hematology was founded in 2017 and follows four main goals:

Develop and share clinically useful tools: Many hematologists create checklists and pathways for quick and easy reference.

Read more

Late-Breaking Abstract Submission

Late-breaking abstract procedureThe official late-breaking abstract submission will open from May 2 to 9, 2025 (09:00 CEST). The full late-breaking abstract submission terms & conditions can be found here.

Read more